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Abstract
Background: Fibrotic idiopathic interstitial pneumonias (fIIP) are a group of fatal lung diseases with largely
unknown etiology and without definitive treatment other than lung transplant to prolong life. There is strong
evidence for the importance of both rare and common genetic risk alleles in familial and sporadic disease. We have
previously used genome-wide single nucleotide polymorphism data to identify 10 risk loci for fIIP. Here we extend
that work to imputed genome-wide genotypes and conduct new RNA sequencing studies of lung tissue to identify
and characterize new fIIP risk loci.
Results: We performed genome-wide genotype imputation association analyses in 1616 non-Hispanic white (NHW)
cases and 4683 NHW controls followed by validation and replication (878 cases, 2017 controls) genotyping and
targeted gene expression in lung tissue. Following meta-analysis of the discovery and replication populations, we
identified a novel fIIP locus in the HLA region of chromosome 6 (rs7887 Pmeta = 3.7 × 10
−09). Imputation of classic
HLA alleles identified two in high linkage disequilibrium that are associated with fIIP (DRB1*15:01 P = 1.3 × 10−7 and
DQB1*06:02 P = 6.1 × 10−8). Targeted RNA-sequencing of the HLA locus identified 21 genes differentially expressed
between fibrotic and control lung tissue (Q < 0.001), many of which are involved in immune and inflammatory
response regulation. In addition, the putative risk alleles, DRB1*15:01 and DQB1*06:02, are associated with
expression of the DQB1 gene among fIIP cases (Q < 1 × 10−16).
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Conclusions: We have identified a genome-wide significant association between the HLA region and fIIP. Two
HLA alleles are associated with fIIP and affect expression of HLA genes in lung tissue, indicating that the potential
genetic risk due to HLA alleles may involve gene regulation in addition to altered protein structure. These studies
reveal the importance of the HLA region for risk of fIIP and a basis for the potential etiologic role of auto-immunity
in fIIP.
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Background
The fibrotic idiopathic interstitial pneumonias (fIIPs) are
a group of lung diseases characterized by progressive fi-
brosis of the alveolar interstitium that leads to significant
morbidity and mortality; median survival of the most
common form, idiopathic pulmonary fibrosis, is 2–3
years after diagnosis. Although pirfenidone [1] and nin-
tedanib [2] have recently been shown to slow the pro-
gression of IPF, only lung transplantation has been
proven to prolong survival. There is evidence for the im-
portance of environmental factors [3–13] and both rare
[14–21] and common genetic variation [22–29] in risk
of fIIP. Cigarette smoking is the strongest known envir-
onmental risk factor for fIIP [30, 31], but up to one third
of individuals with fIIP do not have a history of cigarette
smoking.
Previously, we reported 10 genetic risk loci for fIIP
based on a genome-wide association study; in aggregate,
the genome-wide genotyped SNPs account for 31–33 %
of the variation in risk of developing this disease [32].
The functions of the genes implicated to date in risk of
fIIP indicate that host defense from inhaled insults, bar-
rier function of the alveolar epithelium, and telomere
maintenance are compromised in at least a subset of in-
dividuals with fIIP. While these studies have been reveal-
ing, the majority of risk for fIIP remains unexplained,
suggesting that additional studies to identify genetic
variation are warranted. In the current study, we attempt
to identify additional fIIP genetic risk variants via
genome-wide imputation association analyses using data
from 1616 cases and 4683 out-of-study controls from
our genome-wide association study (GWAS) [32]. We
identify the human leukocyte antigen (HLA) region as a
genetic risk locus for fIIP, demonstrating a potential role
of auto-immunity in fIIP.
Results and discussion
An overview of the study design is shown in Fig. 1.
Imputation study
We imputed genotypes using the HapMap Phase 3 inte-
grated panel [33] using IMPUTE2 [34, 35] and geno-
types at 439,828 SNPs from the Illumina 660 Quad
beadchip that met strict quality control criteria [32]. We
tested for association at 998,072 imputed SNPs under an
additive model for each SNP with imputation informa-
tion as measured by .info > 0.5 using SNPTEST v2 [36].
We adjusted the p-values (divided each test statistic by
1.08, then recomputed p-values) for these imputed SNPs
based on the inflation in the imputation test statistics
(Additional file 1: Figure S1) observed among the
439,828 genotyped SNPs compared to the imputation
test statistics for those SNPs obtained from an exact
mixed model that accounts for subtle stratification and
cryptic relatedness among the cases and controls [37].
After this adjustment and removal of the regions known
to be associated with fIIP [32], neither the Q-Q plot of
p-values (Additional file 1: Figure S2) nor the genomic
control inflation factor (λ = 1.04) suggested systematic
departures from the null hypothesis.
We identified 205 SNPs (Additional file 1: Table S1)
associated with fIIP at a genome-wide level of signifi-
cance (Additional file 1: Figure S3); 204 of these SNPs
are in eight fIIP risk loci (3q26, 4q22, 5p15, 6p24, 7q22,
11p15, 15q14, and 17q21) we had previously reported.
The remaining SNP, rs2169877 (Pimputed = 2.8 × 10
−08), is
on chromosome 15q25 in an intron of the AKAP13
gene. We selected 15 of the genome-wide significant
SNPs (including rs2169877) in addition to 152 SNPs
among the 337 SNPs with 5 × 10−08 < Pimputed <0.0001
for validation and replication genotyping (Additional file
1: Table S2); to avoid redundancy with known associated
SNPs and among the SNPs selected for follow-up, we se-
lected SNPs in weak LD (r2 < 0.5) with previously-known
genome-wide significant SNPs [32] and chose the most
strongly-associated SNP among potential replication
SNPs with pair-wise r2 > 0.8. After genotype quality con-
trol and removal of putative duplicate samples between
the GWAS and replication cases (see Methods), we suc-
cessfully genotyped 1498 of the discovery GWAS cases
for validation (we do not have access to GWAS out-of-
study control DNA) and 878 cases and 2017 controls for
replication at 148 of the SNPs.
After meta-analysis of the imputation and replication
phases, 24 of the 148 SNPs were associated with fIIP at
a genome-wide level of significance (PMeta ≤ 2.8 × 10
−08;
Additional file 1: Table S3). Among these, 6 SNPs
(rs614549, rs7887, rs2844452, rs3020644, rs2280774, and
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rs3117116) represented 1 novel locus for fIIP in the HLA
region at Chromosome 6p21; rs7887 in EHMT2 was the
most strongly-associated SNP (PMeta = 3.7 × 10
−09, Table 1;
regional association shown in Fig. 2). All 6 SNPs had
imputation.info scores >0.98. Rs2169877 at 15q25 was
not genome-wide significant in the meta-analysis
(PMeta =1.6 × 10
−7).
Identification of independent associations within each
locus
Among the genome-wide significant SNPs in regions
previously known to be associated with fIIP, we com-
pared the evidence for association between the newly-
identified SNPs (N = 24) and those we reported previ-
ously (N = 46). Based on both the meta-analysis p-values
and joint analysis of the combined GWAS and replica-
tion cases compared to replication controls, the top SNP
remained the same as originally reported except for the
3q26 and 4q22 regions (Additional file 1: Table S3). At
3q26, rs12696304 near TERC (PMeta = 8.2 × 10
−14) was
more significant than rs6793295 (PMeta = 8.3 × 10
−13), and
at 4q22 in FAM13A, rs2609261 (PMeta = 2.4 × 10
−12) was
more significant than rs2609255 (PMeta = 2.2 × 10
−11).
To assess the evidence for multiple independent asso-
ciation signals within each region accounting for our ori-
ginal GWAS (46 genome-wide significant SNPs) and the
24 SNPs identified in this study, we tested for associ-
ation with each SNP in a given region after adjusting for
the most significant SNP in that region based on the
meta-analysis. We compared the combined case group
(GWAS discovery + replication) to the replication con-
trol group. There was no strong evidence for inde-
pendent signals within each region (Additional file 1:
Table S4). In particular, in the HLA region, no other
SNP was associated with fIIP after adjustment for
rs7887 (all P >0.02; Table 1).
Classic HLA allele associations
To further interrogate the HLA region of association, we
imputed classic HLA alleles for the discovery cohort
using the HLA genotype imputation with attribute bag-
ging (HIBAG) [38] pre-computed imputation probabil-
ities for HLA-A, HLA-B, HLA-C, HLA-DRB1, HLA-DQ
(A1, B1), and HLA-DPB1. The median posterior prob-
abilities for the imputed alleles for each gene were >0.92
for all but the DRB1 gene (Additional file 1: Table S5).
Fig. 1 Overview of Study Design. A discovery imputation GWAS among 1616 cases and 4683 controls was followed by validation and replication
genotyping in 878 cases and 2017 controls. One novel locus was identified on Chromosome 6p21. Classical HLA alleles were imputed using
genotyped SNPs among the GWAS cases and controls and were tested for association with fIIP. Lung tissue gene expression was compared
between a subset of GWAS cases and non-GWAS controls and across genotypes for the most significant 6p21 SNP, rs7887. Gene expression was
also compared across genotypes of the most significant HLA alleles (DQB1*06:02, DRB1*15:01) within the cases with lung tissue expression data
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We tested for association under an additive (on the
log-odds scale) model for each allele (Additional file 1:
Table S6) and with each amino acid. Three alleles were as-
sociated with fIIP at a nominal p-value < 1 × 10−5, the level
of association demonstrated by rs7887 in the GWAS
discovery: DQA1*01:02 (P = 4.8 × 10−6), DQB1*06:02
(P= 6.1 × 10−8), and DRB1*15:01 (P= 1.3 × 10−7); DQB1*06:02
and DRB1*15:01 are very in high LD. While not genome-
wide significant using the standard Bonferroni adjustment
to achieve a study-wide α = .05 (5 × 10−8 corresponds to
.05 divided by 1 million) based on the discovery set, both
alleles are significant after false discovery rate adjustment
for all the genome-wide SNP and HLA imputation statis-
tical tests we conducted (FDR adjusted p-values = 0.015
and .029 for DQB1*06:02 and DRB1*15:01, respectively).
After a step-wise analysis to delineate the conditionally
Table 1 Genome-wide Significant SNPs from Novel HLA Locus Identified in Imputation GWAS
SNP Position Minor
allele
Nearest
gene
P imputeda Rep case
MAFb
Rep Cont.
MAFc
P replicationd P metae OR (95 % CI)
combinedf
P adjustedg
rs614549 31948604 C SLC44A4 5.74 × 10−05 0.32 0.38 5.87 ×10−05 2.09 × 10−08 0.80 (0.73, 0.87) 0.26
rs7887 31972526 A EHMT2 1.18 × 10−05 0.31 0.37 5.84 ×10−05 3.70 × 10−09 0.78 (0.71, 0.86) NA
rs2844452 31990003 C C2 1.69 × 10−05 0.42 0.47 0.00071 4.55 × 10−08 0.81 (0.74, 0.88) 0.26
rs3020644 32002605 G C2 1.13 × 10−05 0.36 0.41 0.00062 2.68 × 10−08 0.80 (0.73, 0.87) 0.28
rs2280774 32036670 T NELFE 1.11 × 10−05 0.29 0.34 0.00096 3.89 × 10−08 0.81 (0.74, 0.89) 0.83
rs3117116 32474995 C BTNL2 9.15 × 10−08 0.15 0.13 0.038 2.65 × 10−08 1.25 (1.10, 1.41) 0.02
aP-value from imputation analysis under additive model using discovery GWAS samples
bMinor allele frequency among replication cases (878)
cMinor allele frequency among replication controls (2017)
dP-value from additive model among replication cases and controls
eP-value from meta-analysis of discovery imputation and replication
fOdds ratio (OR) and 95 % CI for joint analysis comparing subset of GWAS cases (1498) and replication cases (878) to replication controls (2017) based on
observed genotypes; GWAS cases were genotyped at same time as replication cases and controls
gP-value from joint analysis as in (f) with adjustment for rs7887
Fig. 2 Locus-specific plot for HLA region corresponding to discovery imputation GWAS results. The –log10P values (y axis) of the SNPs are shown
according to their chromosomal positions (x axis). The estimated recombination rates (cM/Mb) from the HapMap Project (NCBI Build 36) are
shown as light blue lines, and the genomic locations of genes within the regions of interest in the NCBI Build 36 human assembly are shown as
arrows. SNPs shown in red, orange, green, light blue and blue have r2 ≥ 0.8, r2≥ 0.6, r2≥ 0.4, r2≥ 0.2 and r2 < 0.2 with the most highly-associated
SNP, respectively. SNPs with no r2 information with most-highly associated SNP shown in grey. Circles correspond to genotyped SNPs, squares
correspond to imputed SNPs. P-values correspond to discovery cohort statistical evidence only; meta-analysis p-values can be found in Table 1
and Additional file 1: Tables S1-S3
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independent HLA allele associations (see Methods), only
DQB1*06:02 remained nominally significant. In a model
with both the DQB1*06:02 allele and rs7887, both
remained nominally significant (Padj = 4.8 × 10
−6, and
1.0 × 10−3, respectively; Table 2), indicating the potential
for more than one independent signal in the region (r2 be-
tween rs7887 and DQB1*06:02/DRB1*15:01 = 0.22). Since
the DRB1 alleles were imputed with less confidence
than the DQB1 and DQA1 alleles (median posterior
probability 0.89, 0.97 and 0.94, respectively), and each
of the three HLA alleles are nominally significant
after adjustment for rs7887 (Table 2), it is possible
that the DQB1 alleles appear to be the only inde-
pendent association due to less precision in allele def-
inition for DRB1.
Lung tissue expression studies
To begin to explore the biologic relevance of the associ-
ation evidence, we compared lung tissue gene expression
via amplicon-based targeted RNA-seq between 87 cases
of idiopathic pulmonary fibrosis (IPF, the most common
form of fIIP) and 70 unaffected subjects for 66 genes in
the 1.54 Mb of DNA defined by HLA region association
(Additional file 1: Table S7); of the 86 genes annotated
in the region, 75 could be designed (DQA1 and DQB1
not among them) and 9 did not pass QC thresholds (see
Methods). We identified 34 genes that were differentially
expressed in lung tissue from patients with IPF vs. con-
trols at an FDR of 0.05 (Additional file 1: Table S8); 21
were differentially expressed at an FDR of <1 × 10−3
(Fig. 3; Additional file 1: Table S8). Eight of these 21
genes have a known immune or inflammatory function
(C6orf25, LTA, LTB, AGER, HLA-DOB, C4A, C4B, and
MICA). In addition, two of the genes (HSPA1L and
HSPA1B) encode heat-shock proteins important for me-
diating protein folding, a mechanism thought to be in-
volved in the pathogenesis of IPF [39].
To determine which of the gene expression changes
are more likely important for development of disease as
opposed to a result of the disease process, we explored
whether either rs7887 or the HLA risk alleles are expres-
sion quantitative trait loci for genes in the region. We
tested whether the alleles at rs7887 were associated with
expression among the cases and controls separately. The
alleles at rs7887 were not associated with expression
of any gene after FDR correction in either group
(Additional file 1: Table S9). Among cases, both the
DRB1*15:01 and DQB1*06:02 alleles were associated
with expression of the AIF1 gene (Q = 1.2 × 10−5 and
Q = 1.2 × 10−5, respectively, Additional file 1: Tables
S10 and S11); we were not able to infer HLA alleles
for the controls in the RNA-seq study since they did
not have genome-wide genotyping available. Several
HLA genes, including the DQB1 gene, were not repre-
sented in our RNA-seq expression data, but were repre-
sented in existing Affymetrix gene array expression data
for 66 IPF cases. The DRB1*15:01 and DQB1*06:02 alleles
were associated with increased expression of the DRB5
(Q = 6.7 × 10−22 and Q = 1.06 × 10−21, respectively) and
DQB1 (Q = 8.7 × 10−10 and Q = 1.93 × 10−17, respectively)
genes, suggesting that the alleles may have etiologic effects
through more than just the structure of their respective
binding proteins.
Discussion
Similar to our other GWAS loci, the HLA fIIP risk locus
will require follow-up resequencing in a large number of
cases and controls to define the independent variant(s)
contributing to fIIP risk. Several other small studies have
implicated the HLA region in fIIP with little consensus
on the alleles responsible [40–43]. Of particular interest
given our findings, the DRB1*15:01 allele has been re-
ported to be associated with IPF among a small sample
from China [41]. In the time since we conducted the im-
putation analyses and conducted replication genotyping,
more comprehensive imputation panels have been made
available. We have conducted further imputation ana-
lyses based on the 1000 genomes panel; while there are
no additional genome-wide signals in the absence of rep-
lication genotyping, there are additional SNPs that
Table 2 HLA Allele Associations from GWAS Discovery
Dosage frequencya Best guess countb Univariate resultsc Adjustedd rs7887e
Allele Cases Controls Cases Controls OR (95 % CI) P OR (95 % CI) combined P adjusted P adjusted
DQA1*01:02 0.22 0.18 703 1725 1.28 (1.15, 1.42) 4.84 × 10−06 1.25 (1.12, 1.39) 5.55 × 10−5 1.56 × 10−4
DQB1*06:02 0.15 0.12 505 1131 1.40 (1.24, 1.58) 6.05 × 10−08 1.34 (1.18, 1.52) 4.84 × 10−6 1.03 × 10−3
DRB1*15:01 0.16 0.12 513 1151 1.37 (1.22, 1.54) 1.29 × 10−07 1.31 (1.16, 1.48) 9.94 × 10−6 9.90 × 10−4
aEstimated allele frequency based on posterior probabilities of allele assignments
bEstimated allele count based on posterior probabilities of allele assignments
cOdds ratio, 95 % Confidence Interval (CI), and P-value based on GWAS cases compared to GWAS controls for each allele alone
dOdds ratio, 95 % Confidence Interval (CI), and P-value based on GWAS cases compared to GWAS controls adjusted for rs7887
eP-value for rs7887 based on GWAS cases compared to GWAS controls adjusted for HLA allele
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would be candidates for follow-up based on the screen-
ing approach we used in this study (Additional file 1:
Table S12).
Our findings should be understood in the context
of fibrotic interstitial lung disease, which is a rela-
tively common manifestation of several immune-
related disorders, including scleroderma, rheumatoid
arthritis, and systemic lupus erythematosis. Interest-
ingly, the DRB1:15:01 allele has been reported to be
protective for development of systemic sclerosis
among White and Hispanic subjects [44]. While we
explicitly excluded cases with recognized connective
tissue disease-associated or other known syndromic
forms of fIIP, our findings highlight the concept that
auto-immunity may drive the development of fIIP in
a subset of patients with this disease. A recent case
series indicated that 29 % of biopsy-confirmed IPF
patients (that is, those without a characterized con-
nective tissue disease or other known cause of their
ILD) who underwent serology testing had a positive
serology for auto-immunity [45]. In addition, the
DRB1*15 and DQB1*06 alleles have been associated
with interstitial lung disease in a sample of rheuma-
toid arthritis patients in Japan [43].
Conclusions
We have identified the HLA region as associated with
fIIP. Two strongly-linked HLA alleles are associated with
fIIP and affect expression of HLA genes in lung tissue,
indicating that the potential genetic risk due to HLA al-
leles may involve gene regulation in addition to altered
protein structure. In aggregate, the genome-wide geno-
typed and imputed SNPs are estimated to account for
35 % of the variability in risk of fIIP, a disease that was
previously thought to be idiopathic. Importantly, the
HLA locus and other risk loci will facilitate the identifi-
cation of genes and processes that are involved in the
etiology of fIIP that may lead to breakthroughs in dis-
ease pathogenesis and intervention. In particular for the
HLA locus, linking the putative risk alleles to differential
expression in tissue from the lung is one way to narrow
the list of expression differences between cases and
AGER
AIF1
APOM
ATP6V1G2
C2  
C4A
C4B
C6orf25
C6orf47
CFB
EGFL8
GPSM3
HLA-DOB
HLA-DQB2
HSPA1A
HSPA1B
HSPA1L
LTA
LTB
LY6G5B
LY6G6D
LY6G6F
MICA
MICB
NEU1
NOTCH4
PRRT1
RNF5P1
SAPCD1
SLC44A4
SNORA38
TNXA
VARS
VWA7
6
9
12
15
-3 -2 -1 0 1 2
Adjusted log2 Fold Change
T
ra
ns
cr
ip
t A
bu
nd
an
ce
 
 IP
F
 C
as
es
 (
lo
g2
 N
or
m
al
iz
ed
 R
ea
d 
C
ou
nt
)
q value 0.001 to 0.05 0.0001 to 0.001 10e-09 to 0.0001 < 10e-09
Direction down-regulated up-regulated
Fig. 3 Targeted RNA-Seq Expression Differences between IPF and Control Lung. The size of the dots corresponds to q-value; larger dots have
smaller q-values. The color of the dots corresponds to the direction of expression changes; genes in blue have lower expression in case lung
tissue compared to control lung tissue, genes in red have higher expression
Fingerlin et al. BMC Genetics  (2016) 17:74 Page 6 of 12
controls to those that are more likely to be drivers of
disease risk as compared to consequences of the disease
process. In addition, the association between the puta-
tive HLA risk alleles and transcript abundance of HLA
genes provides alternative avenues of investigation into
the functional role of the alleles.
Methods
Study populations, ethics, permission and consent
Case definition
We used standard criteria established by the American
Thoracic Society/European Respiratory Society [46] to
determine diagnostic classification of all patients in the
discovery and replication phases. We excluded cases
with known explanations for development of fibrotic
FIIP including infections, systemic disorders, or relevant
exposures (e.g. asbestos). To maximize power and
minimize potential confounding by ancestry, we in-
cluded only non-Hispanic white (NHW) participants
that had been recruited as part of existing studies. All
subjects gave written informed consent as part of
IRB-approved protocols for their recruitment at each
site (National Jewish Health, InterMune, Vanderbilt
University, National Heart Lung and Blood Institute,
Duke University, University of Pittsburgh, University
of Texas Southwestern, Centre National de Génotypage,
National Institute for Health Research Biomedical
Research Unit, Royal Brompton Hospital, University
of California San Francisco) and the GWAS study was ap-
proved by the National Jewish Health IRB and Colorado
Combined Institutional Review Board (COMIRB).
GWAS discovery
We genotyped 1914 patients with fIIP from 7 cohorts
(familial interstitial pneumonia [n = 566], National Jewish
Health FIIP population [n = 238], InterMune IPF trials
[n = 720], UCSF [n = 66], Vanderbilt University FIIP
population [n = 105], and the National Heart Lung
and Blood Institute Lung Tissue Research Consortium
[n = 219]) and compared them to genotypes from
4683 out-of-study controls. After genotype quality
control, we included 1616 cases in analyses.
A family with familial interstitial pneumonia (FIP) is
defined by the presence of at least 2 cases of definite or
probable IIP in individuals who are 3rd degree relatives
or closer. Recruitment of families based at three major
referral centers (Vanderbilt University, Duke University
and National Jewish Health) has been ongoing since
1999. We included only 1 fIIP case among first degree
relatives. The National Jewish Health fIIP cohort consists
of patients with sporadic fIIP who were clinically
evaluated and enrolled at National Jewish Health as
part of ongoing natural history studies. Details of the
recruitment criteria for the cases from the Intermune
IPF γ-Interferon Intervention Trial have been de-
scribed in detail [47]. Briefly, eligible patients had IPF,
were 40 to 79 years old with clinical symptoms for at
least 3 months and evidence of disease progression
within the previous 12 months. We included all avail-
able cases regardless of treatment assignment. The
National Heart Lung and Blood Institute Lung Tissue
Research Consortium (NHLBI LTRC) was established
to provide lung tissue and DNA for the research
community. We included DNA from those subjects
with a diagnosis of fIIP after receiving permission
from the NHLBI LRTC.
We used de-identified control genotypes generated at
Centre d’Étude du Polymorphisme Humain (CEPH) as
part of other studies. Potential controls were those who
self-reported NHW, had been genotyped on the same
platform as our cases, and were appropriately approved
for use as controls in other studies. We selected a subset
of controls, corresponding to approximately 3 controls
for 1 case, based on genetic similarity to the cases which
passed our genotyping quality control thresholds as pre-
viously described [32].
Replication
We genotyped a total of 978 NHW fIIP cases and 2052
NHW controls for replication of the top SNPs from
the GWAS. The replication controls were a subset
(n = 1926) of the controls from the Chronic Obstructive
Pulmonary Disease (COPD) Gene Study [48] and 126 con-
trols from the University of Pittsburgh. We selected con-
trols to be frequency matched to the replication cases
based on age and gender. To exclude putative duplicate
cases within the replication and between the GWAS and
replication case groups, we calculated the kinship co-
efficient for each pair of individuals using the 329
SNPs constituting the combined replication genotyp-
ing from the original (181 SNPs) and imputation (148
SNPs) GWAS studies. There were no duplicate indi-
viduals within the GWAS; we removed 39 replication
cases with kinship coefficient > .45 with either a
GWAS case or another replication case. After duplicate
removal and genotype quality control (see below), we in-
cluded 878 cases and 2017 controls in any analyses that
included replication samples.
Expression
We measured gene expression on a subset of Lung Tis-
sue Research Consortium (n = 50) and National Jewish
Health fIIP cases from the GWAS (n = 37) and National
Jewish Health controls (n = 70). Whole-lung samples
were obtained from International Institute for the Ad-
vancement of Medicine (Edison, NJ). Eligible cases and
controls had sufficient RNA from lung tissue biopsy
available for assay; cases with IPF were preferentially
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chosen over other fIIP diagnoses. Treatment status of
IPF cases were not available for the 37 National Jewish
Health cases; of the 50 LTRC IPF patients included in
the RNA expression analysis, 33 (66 %) were on systemic
steroid treatment, 14 (28 %) were not on systemic ster-
oid treatment and 3 (6 %) did not have information on
treatment status.
Genotyping
Genome-wide genotyping was carried out at CEPH using
the Illumina 660 Quad beadchip (www.illumina.com).
Details of the quality control and experiments have been
reported in detail previously [32]. Replication genotyping
was carried out at the Biomedical Genomics Center at the
University of Minnesota. For validation and replica-
tion genotyping of imputation association results, we
attempted to genotype 167 SNPs with adjusted imputation
P-values less than 0.0001 (see Statistical Analyses) in 1027
independent cases and 2052 replication controls. In
addition, to allow follow-up joint statistical tests (using
raw genotypes from both GWAS cases and replication
cases and controls) and validate the imputation geno-
types, we also genotyped a large subset of GWAS
cases (N = 1578). Details of the validation assays are
described below. After genotyping quality control, we
included 878 cases and 2017 controls in the replica-
tion, meta- and joint analyses and 1498 of the GWAS
cases in the joint analyses.
Prior to genotyping, all samples were quality con-
trolled by real-time Q-PCR quantitation (“QC1”) and
uniplex genotyping using Taqman (“QC2”). Samples that
failed QC1 or QC2, although carried forward through
genotyping, were later removed from analysis.
Validation genotyping was accomplished with a com-
bination of multiplexed (Sequenom iPLEX) and uniplex
(Taqman) assays. First, assay design for multiplexed
Sequenom iPLEX genotyping was performed on an
input set of 167 SNPs (Additional file 1: Table S2),
using a combination of web-based (AssayDesigner
Suite, www.sequenom.com) and desktop (AssayDesigner)
software tools (Sequenom, San Diego). Sequenom iPLEX
genotyping is based on multiplexed locus-specific PCR
amplification, multiplexed single-based extension (SBE)
from locus-specific amplicons, and multiplexed resolution
of SBE products base calling using matrix-assisted laser
desorption/ionization time-of-flight (MALDI-TOD) mass
spectrometry.
Primers for the Sequenom assay were purchased from
IDT (Coralville, Iowa), and all steps of the iPLEX proced-
ure were carried out using reagents and methods from
Sequenom (San Diego, CA) according to the manufac-
turer’s instructions. Reactions were carried out in 384-well
plates and analyzed using the Sequenom MassARRAY
Analyzer 4 system with iPLEX Gold reagents and
SpectroCHIP arrays. Results were analyzed using a com-
bination of commercial software (Typer 4, Sequenom) and
custom tools for data management. Of 167 assays in 6
multiplexes, 148 were successful in generating usable geno-
typing data.
Gene expression
Total RNA was isolated from approximately 30 mg of
snap-frozen or RNA-later preserved lung tissue using
the Ambion mirVana kit (Life Technologies). RNA con-
centration was determined by Nanodrop ND-1000
(Thermo Scientific) and RNA integrity was determined
using the 2100 Bioanalyzer (Agilent). cDNA single
strand conversions were performed using the Super-
script III.
Statistical analyses
Statistical analyses for the discovery GWAS based on
observed genotypes, including selection of out-of-study
controls, removal of genetic outliers, SNP quality control
and tests for association have been described previously
in detail [32].
Imputation
We imputed genotypes using the combined case and
control discovery samples for all HapMap SNPs not on
the Illumina 660 Quad beadchip across the entire gen-
ome. We used the multi-population reference panel data
from HapMap3 for pre-phasing using Shapeit with ap-
propriate default parameters [49, 50]. We performed im-
putation using IMPUTE2 [34, 35] and tested for
association at only those SNPs with imputation informa-
tion as measured by .info > 0.5 using SNPTEST (v2;
[36]) with multiple Newton–Raphson iterations to esti-
mate parameters. We adjusted for sex in all models. We
computed the inflation factor across all the SNPs as the
ratio of the median of the observed 1 degree of freedom
chi-square test statistic obtained from the SNPTEST p-
value to the theoretical median of 1 degree of freedom
chi-square random variable. We adjusted the imputed p-
values based on a comparison between the imputation
test statistics and exact mixed model test statistics (from
GEMMA [37]) for SNPs that were genotyped. For
439,827 SNPs that were genotyped and also imputed
with .info > 0.5 (see Additional file 1: Figure S4 for distri-
bution of .info scores), we computed the inflation factor
as the ratio of the median of the observed 1 degree of
freedom chi-square test statistics obtained from
SNPTEST p-value from genotyped snps and the theoret-
ical median of 1 degree of freedom chi-square random
variable. We then computed adjusted imputed p-values
across the genome by dividing the observed chi-square
test statistic by the inflation factor. We compared the
distribution of these adjusted p-values obtained under
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the additive model to that expected under the null hy-
pothesis of no association across the genome and report
the quantile-quantile (Q-Q plot) and genomic inflation
factor (λ) to verify the absence of systematic biases. We
selected a subset of SNPs with an adjusted imputation
p-value <0.0001 for follow-up in the replication popula-
tions. Within novel loci, we selected the top SNP within
a 500 kb window, and then only selected another SNP if
that SNP had an estimated r2 < 0.8 with the top SNP.
We continued this process until all remaining SNPs had
r2 ≥ 0.8 with at least one selected SNP. Within
previously-known loci, we used the top SNP from our
original GWAS, and then only selected another SNP if
that SNP had an estimated r2 < .5 with the top SNP.
Replication association
We tested for association between each replication SNP
and fIIP under an additive model (on the log-odds scale)
in the replication cases and controls and estimated odds
ratios and 95 % confidence intervals using PLINK. For
SNPs with minor allele frequency < 5 %, we computed a
permutation-based p-value with 100,000 permutations.
The p-values were used in the meta-analysis of the
GWAS and replication cohorts; based on the low
level of imbalance in our study and the total count of
minor alleles for the SNPs we tested, the meta-
analysis should have appropriate maintenance of the
type I error rate [51].
Meta-analysis
To obtain a joint measure of association between each
of the 148 successfully genotyped SNPs in the replica-
tion set and fIIP, we performed a meta-analysis of the
GWAS and replication results using the p-values from
each analysis using METAL (http://www.sph.umich.edu/
csg/abecasis/metal/). We used the weighted inverse
normal method with weight equal to the square root
of the total sample size in the ith study. SNPs with
PMeta < 5 × 10
−8 were considered genome-wide statisti-
cally significant. We created a locus-specific plot [52]
of the discovery GWAS imputation results for the
newly-identified chromosome 6 region that was genome-
wide significant in the meta-analysis.
Multi-SNP models
To assess the independence of effects of the genome-
wide significant SNPs from the meta-analysis, we used
logistic regression models within each locus using the
combined case group (GWAS and replication) and the
replication controls. Specifically, within each locus with
a genome-wide significant SNP, we tested for association
between fIIP and each of the other validation panel
SNPs within that locus after adjusting for the most
significantly associated SNP in that locus (on chromo-
some 11p15, we adjusted for rs35705950).
HLA allele imputation and statistical analyses
Classical human leukocyte antigen (HLA) alleles at
HLA-A,-B,-C,-DPB1,-DQA1,-DQB1, and -DRBI were im-
puted using the R-package HIBAG [38]. HIBAG uses an
ensemble classifier and bagging techniques to arrive at
an average posterior probability. The HIBAG-provided
European-Ancestry reference panel was utilized for im-
putation. To account for imputation uncertainty, the al-
lele dosage was utilized for all analyses. To filter-out
extremely low frequency alleles, potentially yielding un-
stable estimates, a minimum best guess allele count of
10 was required in either the cases or controls for all al-
leles modeled. We tested for association between each of
the alleles and fIIP using logistic regression, adjusting
for the top three principal components of SNP variation,
age and sex. We conducted a step-wise regression across
all the imputed alleles, removing variables not independ-
ently associated with fIIP at the .01 level after adjust-
ment for the other alleles in the model. Finally, we
tested for association between pulmonary fibrosis and
each of DRB1*15:01 and DQB1*06:02 adjusted for
rs7887 and the first three principal components, age and
sex, to determine the independence of effects.
RNA-seq expression analyses
After verifying that our amplicon-based targeted RNA-
seq protocol achieved excellent enrichment for the small
target regions, we used these regions (one per gene) to
estimate gene expression. We used RSEM to assign
reads to targeted regions using an EM algorithm. We re-
moved one sample with fewer than 20,000 total reads
and nine genes in the HLA region with fewer than 25
reads in more than 25 samples. We tested for differential
gene expression in the lung between 87 cases and 70
controls with EdgeR36, using a negative binomial regres-
sion for the RNA-seq counts for each gene, adjusting for
age and sex. A q-value < .05 was considered statistically
significant. We used negative binomial regression, adjust-
ing for age, sex, and total number of reads, to test for as-
sociation between expression and rs7887 allele separately
for cases and controls; we tested for association between
alleles DRB1*15:01 and DQB1*06:02 and expression
among cases only since these alleles could not be imputed
for these controls without genome-wide SNP data.
Additional file
Additional file 1: Tables S1. 205 SNPs Associated with IIP at 5 × 10−8 in
Imputation Analysis. Table S2: SNPs with 5×10−8 < Pimputed-adjusted < .0001.
Table S3: GWAS-Significant SNPs after Meta-Analysis in All Regions (Most
Significant in Region in Bold Type). Table S4: Table of 70 SNPs (46 original,
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Imputation Accuracy Summary. Table S6: HLA Allele Association with
IIP. Table S7: Chromosome 6p21 genes studied via RNA-seq. Table S8:
Differential Expression by Case–control Status. Table S9: Differential
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using 1000 Genomes Reference. Figure S1: Q-Q plots of P-values from
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values from GEMMA analysis (see manuscript statistical methods for details).
Figure S2: Q-Q plot of imputed (adjusted) p-values (inflation factor = 1.04)
after genomic control correction. Figure S3: Imputation GWAS Results Fig. 1:
Imputation GWAS results with 1616 cases and 4683 controls under additive
model. SNPs above red line were genome-wide significant at P < 5 × 10-8. A
subset of these SNPs and SNPs between red and blue lines, corresponding
to 5 × 10−8 < P-value < .0001, were selected for follow-up and genotyped in
878 cases and 2017 controls. Figure S4: Histogram of. INFO Scores from
SNPTest. Only SNPs with .INFO >0.5 Included. Figure S5: Comparison of
SNPTest p-values after genomic control (see manuscript statistical methods)
and GEMMA dosage-values. GEMMA dosage p-values computed after initial
study complete. (DOCX 8917 kb)
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